Medical cannabis products
Medical cannabis has been legalized in Australia since 2016, and since then, a growing number of patients have been using cannabis products to treat various medical conditions. Medical cannabis is authorized by the Therapeutic Goods Administration (TGA), and patients must have a prescription from an authorized medical practitioner to access these products.
Among the many companies that produce medical cannabis products in Australia, MOCA Health is an organic cannabis provider that has become increasingly popular due to its focus on using cutting-edge technology to create top-quality cannabis products. In this overview, we will look at the various medical cannabis products that can be prescribed in Australia, with a specific focus on MOCA Health's organic cannabis products.
Understanding Medical Cannabis
Before we dive into specifics, it's important to understand what medical cannabis is and how it works. Cannabis contains over 100 different cannabinoids, which are chemical compounds that interact with the body's endocannabinoid system (ECS). The ECS is a complex network of receptors and neurotransmitters that help regulate various physiological processes, such as mood, appetite, sleep, pain, and immune function.
The two primary cannabinoids found in cannabis are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the compound responsible for the psychoactive effects of cannabis, while CBD is non-intoxicating and has been shown to have therapeutic properties. THC and CBD work together to produce a range of medicinal benefits, such as reducing chronic pain, easing anxiety, improving mood, and promoting relaxation.
Medical cannabis products come in different forms, such as oils, capsules, vapes, tinctures, and topicals. The type of product recommended depends on the patient's medical condition, symptoms, and individual preferences. Medical practitioners are trained to assess patients and make appropriate recommendations based on the latest research and clinical evidence.
References
Mechoulam, R., & Gaoni, Y. (1967). Recent Advances in the Chemistry of Hashish. Fortschritte der Chemie organischer Naturstoffe / Progress in the Chemistry of Organic Natural Products, 25, 175-213. doi: 10.1007/978-3-7091-8596-8_5
Pertwee, R. G. (2008). The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: Δ9-Tetrahydrocannabinol, Cannabidiol and Δ9-Tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199-215. doi: 10.1038/sj.bjp.0707442
Di Marzo, V. (2008). Targeting the Endocannabinoid System: To Enhance or Suppress? Nature Reviews Drug Discovery, 7(5), 438-455. doi: 10.1038/nrd2553
Ligresti, A., et al. (2006). Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma. Journal of Pharmacology and Experimental Therapeutics, 318(3), 1375-1387. doi: 10.1124/jpet.106.105247
Pacher, P., Bátkai, S., & Kunos, G. (2006). The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews, 58(3), 389-462. doi: 10.1124/pr.58.3.2
Russo, E. B. (2008). Cannabinoids in the Management of Difficult to Treat Pain. Therapeutics and Clinical Risk Management, 4(1), 245-259. doi: 10.2147/tcrm.s1928
Pertwee, R. G. (2010). Receptors and Channels Targeted by Synthetic Cannabinoid Receptor Agonists and Antagonists. Current Medicinal Chemistry, 17(14), 1360-1381. doi: 10.2174/092986710790980005
Mechoulam, R., et al. (1998). Cannabidiol—Recent Advances. Chemistry & Biodiversity, 4(8), 1678-1692. doi: 10.1002/chin.199852206
These references provide scientific insights into the presence of cannabinoids in cannabis and their interactions with the endocannabinoid system. They cover various aspects, including the pharmacology of cannabinoids, their potential therapeutic applications, and their effects on the body.
